Kura Oncology (KURA) Price & Analysis

Compare

809 Followers

KURA Stock Chart & Stats

$8.50

-$0.35(-4.35%)

At close: Jan 08 4:00 PM EST

$8.50

-$0.35(-4.35%)

Day’s Range― - ―

52-Week Range$5.41 - $12.49

Previous CloseN/A

Volume631.17K

Average Volume (3M)1.35M

Market Cap

$739.65M

Enterprise Value$672.53M

Total Cash (Recent Filing)$549.66M

Total Debt (Recent Filing)$19.47M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Mar 05, 2026

EPS Estimate

-0.64

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding87,017,520

10 Day Avg. Volume1,515,361

30 Day Avg. Volume1,350,926

Financial Highlights & Ratios

PEG Ratio1.50

Price to Book (P/B)1.81

Price to Sales (P/S)13.93

P/FCF Ratio5.61

Enterprise Value/Market Cap0.91

Enterprise Value/Revenue6.46

Enterprise Value/Gross Profit6.67

Enterprise Value/Ebitda-3.05

Forecast

1Y Price Target

$30.14

Price Target Upside254.59% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-3.25

Revenue Forecast (FY)$134.29M

Bulls Say, Bears Say

Bulls Say

Clinical Guideline AdoptionPublication of combination trial data could support inclusion in clinical treatment guidelines, which would broaden physician prescribing and accelerate adoption of the menin inhibitor in relevant AML settings.

Financial Position And Cash RunwayA strong cash balance and non-dilutive collaboration revenue provide flexibility to fund ongoing clinical development and commercial activities without immediate reliance on equity financing.

Regulatory Approval And Commercial LaunchRegulatory approval and initial commercial uptake of Komzifti establish an early revenue stream and market presence for the lead therapy, supporting expectations of sequential sales growth.

Bears Say

Clinical Data MaturityEarly MRD kinetics, depth of remission measures, and limited follow-up remain immature relative to competing menin-backbone triplets, creating uncertainty about long-term comparative efficacy and adoption.

Share Dilution RiskAnalyst cautions that increases in share count from equity raises or issuances could dilute earnings per share and weigh on reported quarterly metrics and investor returns.

Kura Oncology News

Kura Oncology management to meet with Citizens

Group Dinner Meeting with Management in Miami on March 11 hosted by Citizens. Published first on TheFly –...

2d ago

KURA

Kura Oncology reports inducement grants under Nasdaq listing rule

Kura Oncology (KURA) announced that on February 2, 2026, the Compensation Committee of the Company’s Board of Directors...

27d ago

KURA

Kura Oncology price target lowered to $29 from $30 at BofA

BofA analyst Jason Zemansky lowered the firm’s price target on Kura Oncology (KURA) to $29 from $30 and...

30d ago

KURA

KURA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Kura Oncology (KURA) is scheduled to report 4th quarter earnings on 03/05/2026, before the market opens. Regarding Q4...

2d ago

KURA

Kura Oncology Tightens Governance with Amended Bylaws

The latest update is out from Kura Oncology ( ($KURA) ). On January 28, 2026, Kura Oncology’s board...

1M ago

KURA

3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all...

2M ago

WVE

KURA

Kura Oncology price target lowered to $20 from $25 at Leerink

Leerink lowered the firm’s price target on Kura Oncology (KURA) to $20 from $25 and keeps an Outperform...

2M ago

KURA

Kura Oncology reports inducement grants under Nasdaq listing rule

Kura Oncology (KURA) announced that on January 2, the Compensation Committee of the Company’s Board of Directors granted...

2M ago

KURA

Kura Oncology’s Promising Clinical Data and Strategic Partnerships Justify Buy Rating

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Kura Oncology, retaining the price target of...

3M ago

KURA

Positive Outlook for Kura Oncology Driven by Promising Clinical Trials and Strategic Advancements

Kura Oncology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

3M ago

KURA

Kura Oncology, Kyowa Kirin report combination data for KOMZIFTI with ven/aza

Kura Oncology (KURA) and Kyowa Kirin announced new data demonstrating a favorable safety profile and encouraging antileukemic activity...

3M ago

KURA

Kura Oncology Announces First U.S. Sale of KOMZIFTI

Kura Oncology ( ($KURA) ) has shared an announcement. On December 2, 2025, Kura Oncology announced the first...

3M ago

KURA

Kura Oncology completes first U.S. commercial sale of KOMZIFTI

Kura Oncology (KURA) announced the first U.S. commercial sale of KOMZIFTI has been completed. Under Kura’s collaboration and...

3M ago

KURA

Kura Oncology’s Growth Potential Boosted by KOMZIFTI’s NCCN Inclusion and Competitive Advantages

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kura Oncology. The associated price target...

3M ago

KURA

KURA FAQ

What was Kura Oncology’s price range in the past 12 months?

Kura Oncology lowest stock price was $5.41 and its highest was $12.49 in the past 12 months.

What is Kura Oncology’s market cap?

Kura Oncology’s market cap is $739.65M.

When is Kura Oncology’s upcoming earnings report date?

Kura Oncology’s upcoming earnings report date is Mar 05, 2026 which is today.

How were Kura Oncology’s earnings last quarter?

Currently, no data Available

Is Kura Oncology overvalued?

According to Wall Street analysts Kura Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kura Oncology pay dividends?

Kura Oncology does not currently pay dividends.

What is Kura Oncology’s EPS estimate?

Kura Oncology’s EPS estimate is -0.64.

How many shares outstanding does Kura Oncology have?

Kura Oncology has 87,017,520 shares outstanding.

What happened to Kura Oncology’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kura Oncology?

Currently, no hedge funds are holding shares in KURA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kura Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-65.10%

Trailing 12-Months

Asset Growth

35.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology (KURA) Earnings & Revenues

Historic Earnings Reports

KURA Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong focus on advancing clinical development, particularly for ziftomenib, with significant progress in trials and preparations for a potential FDA approval. Despite financial challenges, the company's strategic partnerships and clinical advancements position it well for future growth. The sentiment is positive, driven by strong clinical and commercial progress.View all KURA earnings summaries

KURA Stock 12 Month Forecast

Average Price Target

$30.14

▲(254.59% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","32":"$32","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14,23,32,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.27,10.71076923076923,13.151538461538461,15.592307692307692,18.033076923076923,20.473846153846154,22.914615384615384,25.355384615384615,27.796153846153846,30.236923076923077,32.67769230769231,35.11846153846154,37.559230769230766,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.27,9.952307692307691,11.634615384615383,13.316923076923077,14.999230769230769,16.68153846153846,18.363846153846154,20.046153846153846,21.728461538461538,23.41076923076923,25.09307692307692,26.775384615384613,28.45769230769231,{"y":30.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.27,9.172307692307692,10.074615384615385,10.976923076923077,11.87923076923077,12.78153846153846,13.683846153846154,14.586153846153845,15.48846153846154,16.39076923076923,17.293076923076924,18.195384615384615,19.097692307692306,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >